Sinovac Biotech Ltd., of Beijing, said it received site inspection notification for the commercial production facilities of its EV71 vaccine candidate from the CFDA.
Twi Pharmaceuticals Inc., of Taipei, Taiwan, appointed Jianbo Xie chief operating officer. Xie will be responsible for his existing R&D function, as well as production in Chungli and operations in Neihu headquarters. He was formerly R&D executive vice president.
HONG KONG – South Korean drugmaker Celltrion Inc. has received marketing approval for its star product, Remsima, an infliximab biosimilar, in Brazil and Venezuela, marking the beginning of the company's expansion into Latin America.
HONG KONG – The discovery of a novel mechanism for blood pressure (BP) regulation in a study by researchers at the Riken Brain Science Institute (BSI) in Wako, Japan, could have important implications for the control of elevated BP and may lead to the discovery of new antihypertensive medications.
HONG KONG – In a move that could lead to more and easier access to better medicines at the local level, China plans to eliminate fixed prices for drugs next month. And, despite public concerns, the regulator said drug prices will not shoot up even after price caps are taken away.
SHANGHAI – Each year investors looking to ride the next big wave of opportunity convene at China's Healthcare Investment Conference to test the waters. This year, the promise of technology to tackle some of China's most complicated health care woes, summed up by the term e-Health, generated the most buzz.
HONG KONG – With a third round of funding in hand, Taiwanese contract manufacturer and biosimilars maker JHL Biotech Inc. is that much closer to its first filing in Europe and an IPO later this year.
SAN FRANCISCO – With international dealmaking often a key element of the biopharma asset development adventure, the path to success in Japan took center stage during the first day of Allicense, an annual pilgrimage for the industry's top business development pros.
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, and Takeda Pharmaceutical Co. Ltd., also of Osaka, said their license agreement, inked in 2011 for the joint development and exclusive commercialization of pharmaceutical products containing lurasidone hydrochloride (Latuda), an atypical antipsychotic agent, in Europe, will be terminated.
HONG KONG – Taigen Biotechnology Co. Ltd. started the first clinical trials of its stem cell mobilizer drug, burixafor (TG-0054), in mainland China. It received regulatory clinical trial approval from the CFDA in 2013 for phase I and II trials as a chemotherapy sensitizer in combination with two chemotherapeutic agents for the treatment of leukemia.
RSS